A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.

@article{Shiraishi2014ADA,
  title={A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.},
  author={Yutaka Shiraishi and Atsunori Yorozu and Toshio Ohashi and Kazuhito Toya and Shoichiro Saito and Toru Nishiyama and Yasuto Yagi and Naoyuki Shigematsu},
  journal={International journal of radiation oncology, biology, physics},
  year={2014},
  volume={90 5},
  pages={
          1069-75
        }
}
PURPOSE To define the optimal dose for (125)I prostate implants by correlating postimplantation dosimetry findings with biochemical failure and toxicity. METHODS AND MATERIALS Between 2003 and 2009, 683 patients with prostate cancer were treated with (125)I prostate brachytherapy without supplemental external beam radiation therapy and were followed up for a median time of 80 months. Implant dose was defined as the D90 (the minimal dose received by 90% of the prostate) on postoperative day 1… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Similar Papers

Loading similar papers…